Microbiome Therapeutics Market is expected to reach US$ 813.38 million by 2030

Procedures Segment to Dominate Microbiome Therapeutics Market During 2022–2030 

According to our new research study on "Microbiome Therapeutics Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the microbiome therapeutics market size is expected to grow from US$ 375.92 million  in 2022 and to reach a value of US$ 813.38 million  by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030. Key factors driving the market growth are the potential of gut microbiota in maintaining human health and the inflow of funds to ameliorate microbiome discovery pipeline. However, the high cost of development and production hinders the microbiome therapeutics market growth.

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in the overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of €13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00027698

Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank), and YSOPIA Bioscienceare among the key companies operating in the microbiome therapeutics market. The companies have been implementing various strategies that contribute to their growth and lead to various changes in the market. The companies have utilized both organic strategies (such as launches, expansion, and product approvals) and inorganic strategies (such as product launches, partnerships, and collaborations).

For instance, in September 2023, YSOPIA Bioscience's filed application for a clinical trial (IND) to begin a Phase 1 study in obesity and related metabolic illnesses was approved.

The report segments the microbiome therapeutics market as follows:

The microbiome therapeutics market, by type, is segmented into therapeutics and procedure. The microbiome therapeutics market, by application, is segmented into metabolic disorders and obesity, diabetes, C. difficile infection, and inflammatory bowel diseases. The microbiome therapeutics market, by end user, is segmented into hospitals and clinics, ambulatory surgery center, and home care. Based on geography, the microbiome therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: The Insight Partners
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com